Genitourinary Cancer

Genitourinary Cancer News & Features

Bladder Cancer Surgery Safe Following Neoadjuvant Immunotherapy

January 21, 2020

Toxicity profile and readmission rates among patients who underwent radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab are in line with previously published series reporting 90-day outcomes after RC with or without neoadjuvant chemotherapy.

Pembrolizumab Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer

Diana Ernst, RPh

January 16, 2020

The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Survey Reveals Perspective on Use of Support Garments Varies Among Patients With a Urostomy

Vicki Moore, PhD

January 14, 2020

Patients’ survey responses ranged from the garments cause discomfort to they alleviate discomfort. Some responses indicated patients face a possible trade-off between comfort and protection in finding the optimal support garment.

FDA Approves Therapy for Advanced Urothelial Cancer

Natasha Persaud

December 19, 2019

Padcev is the first antibody-drug conjugate approved for advanced urothelial cancer patients.

At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progre

Immunotherapy + Chemo May Improve Outcomes in Metastatic Urothelial Cancer

Jody A. Charnow, Editor

October 3, 2019

First-line treatment with both atezolizumab and platinum-based chemotherapy (PBC) is associated with prolonged progression-free survival vs PBC alone in patients with metastatic urothelial cancer, a study found.

Clinical Trial: Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer

Next post in Genitourinary Cancer

Genitourinary Cancer

Bladder Cancer Surgery Safe Following Neoadjuvant Immunotherapy

Pembrolizumab Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer

Survey Reveals Perspective on Use of Support Garments Varies Among Patients With a Urostomy

FDA Approves Therapy for Advanced Urothelial Cancer

Immunotherapy + Chemo May Improve Outcomes in Metastatic Urothelial Cancer

Genitourinary Cancer Clinical Trials

Clinical Trial: Intraoperative Monitoring of the Pelvic Autonomic Nerves (NEUROS)

Clinical Trial: Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT)

Clinical Trial: Maternal Genitourinary Infections and Adverse Perinatal Outcomes

Clinical Trial: Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass

Clinical Trial: Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer

Want to read more?

Pembrolizumab Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer